Fresh analysis reveals that people who discontinue popular GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass much more quickly than those who halt traditional lifestyle programs.
Research printed in a major health publication demonstrates that while obese individuals can lose a large proportion of their total mass while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.
"Individuals purchasing such treatments must be informed of the potential of fast weight regain when the therapy concludes," stated expert Dr. Susan Jebb.
That rate of regain implies a reversion to original weight in about one and a half years.
Analyzing Therapies
The research, which examined 37 of studies involving over 9,000 of participants, compared the results of the injectable medications with conventional dieting.
Scientists note that individuals who lose weight through diet and exercise typically see a more gradual creep back—around 0.1 kg a month—after stopping.
Understanding the Fast Regain
Experts propose the mode of action of the drugs explains the accelerated regain.
The injections imitate a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Artificially providing the hormone levels several times higher than normal could lead to the system to produce less of its own natural hormone, and may also reduce sensitivity to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this GLP-1 'fix' results in appetite is unsuppressed, making overeating far more likely."
A Lifelong Disease?
The NHS advise the jabs for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians contend that, due to the significant potential of relapse, the therapy is often life-long.
This opinion is reinforced by pharmaceutical companies, who state that the results "highlight the persistent character of excess weight," similar to managing conditions like diabetes.
Patient Testimonies
Users who have come off the medication report a powerful return of appetite.
"It was like something that goes on and you're instantly starving," described one woman.
This challenge is compounded if patients have not established lasting dietary or behavioural changes during treatment.
Widespread Adoption
Survey data indicate that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.
- Use is greater among women compared to males.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
Ultimately, experts emphasize that while the jabs are potent tools for weight loss, they are not a permanent solution and long-term success hinges on integrated lifestyle support.
